|
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90
|
March 19, 2023
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
|
March 2, 2023
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research & Clinical Oncology
|
|
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
|
February 23, 2023
|
PC3I Authors Ronac Mamtani |
BJUI Compass
|
|
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
|
February 23, 2023
|
PC3I Authors Ramy Sedhom; Ronac Mamtani |
JAMA Oncology
|
|
Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy
|
December 22, 2022
|
PC3I Authors Daniel Lee; Ronac Mamtani |
BJU International
|
|
Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden
|
November 13, 2022
|
PC3I Authors Ronac Mamtani; Daniel Lee |
Urologic Oncology
|
|
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors
|
August 29, 2022
|
PC3I Authors Kerry Coughlin; Larry Shulman; Ronac Mamtani |
JAMA Network Open
|
|
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
|
August 10, 2022
|
PC3I Authors Ronac Mamtani |
Journal of the National Comprehensive Cancer Network
|
|
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
|
August 9, 2022
|
PC3I Authors Melina Marmarelis; Ronac Mamtani |
Clinical Lung Cancer
|
|
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
|
July 9, 2022
|
PC3I Authors Ronac Mamtani |
JNCI Cancer Spectrum
|
|
Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice
|
June 7, 2022
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Pharmacoepidemiology and Drug Safety
|
|
Correction to: Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma
|
June 2, 2022
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research and Clinical Oncology
|
|
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy
|
May 13, 2022
|
PC3I Authors Ronac Mamtani |
JAMA Oncology
|
|
Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma
|
February 4, 2022
|
PC3I Authors Ronac Mamtani |
Cancer
|
|
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy
|
January 30, 2022
|
PC3I Authors Melina Marmarelis; Ronac Mamtani; Charu Aggarwal |
Clinical Lung Cancer
|
|
Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma
|
January 23, 2022
|
PC3I Authors Ronac Mamtani |
Journal of Cancer Research and Clinical Oncology
|
|
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
|
January 5, 2022
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States
|
December 11, 2021
|
PC3I Authors Samuel Takvorian; Daniel Lee; Roger Kim; Caleb M. Hearn; William Ferrell; Larry Shulman; Ronac Mamtani |
Journal of the National Cancer Institute
|
|
Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights
|
November 10, 2021
|
PC3I Authors Ronac Mamtani |
Journal of Biopharmaceutical Statistics
|
|
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers
|
November 4, 2021
|
PC3I Authors Ronac Mamtani |
JAMA Oncology
|
